New drug combo aims to keep lung cancer in check after chemoradiation

NCT ID NCT07485920

First seen Mar 25, 2026 · Last updated May 05, 2026 · Updated 4 times

Summary

This study tests whether combining two drugs, tislelizumab and nintedanib, can help control limited-stage small cell lung cancer after standard chemoradiotherapy. About 20 adults with this cancer type will receive the drug combination as consolidation therapy. The goal is to see if it delays cancer progression and improves survival, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Qingdao Central Hospital Affiliated to Rehabilitation University

    Qingdao, Shandong, China

    Contact Email: •••••@•••••

  • Qingdao Municipal Hospital

    Qingdao, Shandong, China

    Contact Email: •••••@•••••

  • Weihai Municipal Hospital

    Weihai, Shandong, China

    Contact Email: •••••@•••••

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

    Contact Email: •••••@•••••

  • Zibo Fourth People's Hospital

    Zibo, Shandong, China

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.